RxDoctor Payments Data

Anthony Girardi, MD

Ophthalmology · Glen Cove, NYNPI 1366451148

Payments from drug & device makers

$371in general payments, 2019–2025

Across 18 payments — averaging $20.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$141
  • Novartis$49
  • Amgen$40
  • Akorn Operating Company LLC$37
  • AbbVie$27
  • Dompe US, Inc.$26
  • plus $52 from 3 others

What the payments were for

  • Food & beverage$371100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Alcon6$141
Novartis2$49
Amgen(2 entities)2$40
Akorn Operating Company LLC2$37
AbbVie2$27
Dompe US, Inc.1$26
Bausch & Lomb, A Division Of Bausch Health US, LLC1$22
Eyevance Pharmaceuticals LLC1$16
Kala Pharmaceuticals, Inc.1$14

How this compares

$371 in reported general payments places this provider in the 30th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$333,258
Medicare patients
979
Services billed
4,231

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost31$15,117
RestasisCyclosporine11$13,152
Travoprost67$12,314
CombiganBrimonidine Tartrate/Timolol19$5,318
Latanoprost429$5,086
Prednisolone Acetate185$4,618
MoxifloxacinMoxifloxacin Hcl169$3,547
SimbrinzaBrinzolamide/Brimonidine Tart17$3,386
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat135$3,085
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol14$2,098
Timolol Maleate82$872
Brimonidine Tartrate59$653
Dorzolamide Hcl15$426
Acetazolamide ErAcetazolamide114$220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$27$33,58761 claims
AlconSimbrinza$141$3,38617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Glen Cove

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →